$21.43
2.41% yesterday
Nasdaq, Jul 11, 10:10 pm CET
ISIN
US64049K1043
Symbol
NGNE
Reports
Quarter | Annual
Index
NASDAQ Composite
Sector
Health
Industry
Pharmaceuticals

Neoleukin Therapeutics Inc Stock price

$21.43
+0.51 2.44% 1M
+2.62 13.93% 6M
-1.43 6.26% YTD
-20.34 48.70% 1Y
+0.83 4.03% 3Y
-200.17 90.33% 5Y
-17.57 45.05% 10Y
-217.57 91.03% 20Y
Nasdaq, Closing price Fri, Jul 11 2025
-0.53 2.41%
ISIN
US64049K1043
Symbol
NGNE
Reports
Quarter | Annual
Index
NASDAQ Composite
Sector
Health
Industry
Pharmaceuticals

Key metrics

Basic
Market capitalization
$305.6m
Enterprise Value
$13.1m
Net debt
positive
Cash
$292.6m
Shares outstanding
14.9m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.1
Financial Health
Equity Ratio
92.5%
Return on Equity
-24.2%
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
- | -
EBIT
- | $-114.5m
Net Income
- | $-73.0m
Free Cash Flow
$-71.3m
Growth (TTM | estimate)
Revenue
- | -100.0%
EBITDA
- | -
EBIT
- | -38.7%
Net Income
- | 2.9%
Free Cash Flow
-18.7%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
$-4.8
Short interest
20.0%
Employees
107
Rev per Employee
$10.0k
Show more

Is Neoleukin Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

Neoleukin Therapeutics Inc Stock Analysis

Unlock Scores for Free

Dividends

??

High-Growth-Investing

HGI

??

Levermann

???

Analyst Opinions

13 Analysts have issued a Neoleukin Therapeutics Inc forecast:

11x Buy
85%
2x Hold
15%
More details on Analyst Estimates Including Price Targets

Analyst Opinions

13 Analysts have issued a Neoleukin Therapeutics Inc forecast:

Buy
85%
Hold
15%
Analyst Estimates with Stock Price Targets

Financial data from Neoleukin Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.93 0.93
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
104% 104%
2,431%
- Research and Development Expense 61 61
36% 36%
6,540%
-79 -79
62% 62%
-8,528%
- Depreciation and Amortization 3.20 3.20
2% 2%
344%
EBIT (Operating Income) EBIT -83 -83
58% 58%
-8,872%
Net Profit -75 -75
107% 107%
-8,080%

In millions USD.

Don't miss a Thing! We will send you all news about Neoleukin Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Neoleukin Therapeutics Inc Stock News

Neutral
Business Wire
●
9 days ago
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 4,290 shares of the Company's common s...
Neutral
Business Wire
●
12 days ago
Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced details of Embolden™, the Company's registrational clinical trial designed to evaluate NGN-401 gene therapy for the treatment of females with Rett syndrome in participants ages 3 years...
Neutral
Business Wire
●
about one month ago
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common ...
More Neoleukin Therapeutics Inc News

Company Profile

Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.

Head office United States
CEO Rachel McMinn
Employees 107
Founded 2018
Website www.neurogene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now
The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today